P/E ratio for Moderna (MRNA)

P/E ratio history for Moderna from 2018 to 2023

PE ratio at the end of each year

P/E ratio for similar companies or competitors

Company	P/E ratio	P/E ratio differencediff.	Country
Regulus Therapeutics RGLS	-0.9586	-78.50%	🇺🇸 USA
Merck MRK	54.9	-1,331.69%	🇺🇸 USA
Athersys ATHX	-0.0045	-99.90%	🇺🇸 USA
Alnylam Pharmaceuticals ALNY	-60.0	1,245.33%	🇺🇸 USA
Novartis NVS	26.5	-694.17%	🇨🇭 Switzerland
Arrowhead Pharmaceuticals ARWR	-13.1	193.75%	🇺🇸 USA
Johnson & Johnson JNJ	10.4	-333.09%	🇺🇸 USA
Dicerna Pharmaceuticals DRNA	N/A	N/A	🇺🇸 USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.